Physician Views: How quickly are US patients getting access to Regeneron, Sanofi's Dupixent?

Commercial expectations were already high for Dupixent and are likely to have been raised further by encouraging – if very early – prescription data. Earlier this month, Regeneron Pharmaceuticals said the atopic dermatitis treatment had been prescribed to approximately 3,500 patents in just five weeks – ViewPoints: Regeneron happy to hang its hat on Dupixent’s hot start.

If such momentum is retained, consensus forecast sales are likely to rapidly escalate. Noting also that the US cost-effectiveness organisation ICER has delivered a positive assessment of Dupixent's $31,000 a year price tag, Bernstein analyst Ronny Gal indicated in a note to investors this week that some hedge fund managers are predicting Regeneron and Sanofi's product could deliver Humira-like sales at its peak.

We are some way from those lofty heights, but in the near term, rate of utilisation of Dupixent will also depend largely on how quickly patients can gain access. Upon approval, Regeneron was bullish in its assertion that pharmacy benefit managers would not onerously restrict access; while anecdotal evidence suggests these promises may be largely delivered upon, some healthcare plans are requiring patients to meet additional criteria before they can use Dupixent.

Our latest Physician Views snap poll aims to gauge how easily patients are gaining access to Dupixent and asks US-based dermatologists the following questions…

Dupixent (dupilumab) has now been available for the treatment of moderate-to-severe atopic dermatitis in the US market for approximately six weeks. In your experience, how would you describe overall access to the drug through large pharmacy benefit managers and health plans?

Very poor

Poor

Fair

Good

Excellent    

Approximately what proportion of patients to whom you have prescribed Dupixent have gained access to the drug having failed treatment with only topical agents?  

 

Approximately what proportion of patients to whom you have prescribed Dupixent have gained access to the drug having failed treatment with topical agents and systemic therapies?

 

Approximately what proportion of patients to whom you have prescribed Dupixent have been required to provide documentation of disease over a multi-year period before gaining access to the drug?

 

How would you rate the quality of medical affairs/sales support from Regeneron and Sanofi since the launch of Dupixent?

None

Very poor

Poor

Fair

Good

Excellent    

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com

To read more Physician Views articles, click here.